loading
Schlusskurs vom Vortag:
$1.00
Offen:
$0.9898
24-Stunden-Volumen:
162.13K
Relative Volume:
0.02
Marktkapitalisierung:
$8.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.42M
KGV:
-0.0429
EPS:
-23.3189
Netto-Cashflow:
$-6.75M
1W Leistung:
+7.03%
1M Leistung:
+0.81%
6M Leistung:
-54.09%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$0.9768
$1.04
1-Wochen-Bereich:
Value
$0.8612
$1.06
52-Wochen-Spanne:
Value
$0.575
$23.13

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name
Firmenname
Silexion Therapeutics Corp
Name
Telefon
972-8-6286005
Name
Adresse
12 ABBA HILLEL ROAD, RAMAT GAN
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
SLXN's Discussions on Twitter

Vergleichen Sie SLXN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLXN
Silexion Therapeutics Corp
1.00 8.12M 0 -16.42M -6.75M -23.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten

pulisher
Apr 25, 2025

Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics enters collaboration with Catalent - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 05, 2025

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World

Apr 05, 2025
pulisher
Mar 31, 2025

Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 29, 2025

Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Expands SIL204 Development Plan - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan

Mar 28, 2025
pulisher
Mar 23, 2025

Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion announces completion of expanded development plan for SIL204 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Silexion Therapeutics reaches deal to retire convertible note - Investing.com

Mar 14, 2025
pulisher
Mar 06, 2025

Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal

Mar 06, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer Models - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Positive Data for SIL204 - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion reports initial data from systemic administration of SIL204 - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Positive Efficacy Data for SIL204 in Orthotopic Pancreatic Cancer Models - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - StreetInsider.com

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Can Silexion's New Pancreatic Cancer Drug Stop Metastasis? Early Data Shows 80% Tumor Reduction - StockTitan

Mar 05, 2025
pulisher
Mar 03, 2025

Can Silexion's RNAi Therapy Revolutionize Pancreatic Cancer Treatment? March Data Will Tell - StockTitan

Mar 03, 2025
pulisher
Feb 26, 2025

Is Now The Time To Buy Silexion Therapeutics Corp (NASDAQ: SLXN) Stock? - Stocks Register

Feb 26, 2025
pulisher
Feb 26, 2025

Silexion completes study of SIL-204 in orthotopic pancreatic cancer models - BioWorld Online

Feb 26, 2025
pulisher
Feb 25, 2025

Silexion completes initial study of SIL-204 in pancreatic cancer models - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Silexion Therapeutics Completes Initial Study of SIL-204 in Orthotopic Pancreatic Cancer Models - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Silexion Therapeutics Announces Completion of Initial Study - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can Silexion's RNA Therapy Change Pancreatic Cancer Treatment? Key Study Completed - StockTitan

Feb 25, 2025
pulisher
Feb 23, 2025

Comparing Silexion Therapeutics (NASDAQ:SLXN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

Feb 23, 2025

Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):